ASLAN Pharmaceuticals Pte Ltd
10A Bukit Pasoh Road
148 articles with ASLAN Pharmaceuticals Pte Ltd
ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares
ASLAN Pharmaceuticals Limited announced that it has priced its previously announced underwritten public offering of 5,124,527 American Depositary Shares at a public offering price of $2.50 per ADS.
ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.
ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
3 patients completed 1 month of dosing and achieved average reduction in EASI score of 71%. Maximal efficacy expected at 6 to 8 weeks.
ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”) representing ordinary shares
ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced that new preclinical data characterising ASLAN003 as a potential treatment for acute myeloid leukaemia has been published in the November issue of HaematologicaJournal.
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer
ASLAN to focus on development of ASLAN004 and other promising molecules in its portfolio. Interim topline results from ongoing study of its IL-4/IL-13 blocker mAb expected early 2020
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, reported financial results for the quarter ended 30 September 2019 and provided an update on its clinical activities.
10/28/2019Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
ASLAN Pharmaceuticals Enrolls First Patient in Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis
Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the board, and several major investors.
ASLAN Pharmaceuticals announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil chemotherapy to determine the safety, tolerability and maximum tolerated dose in advanced solid tumours.
Aslan Pharmaceuticals Presents Late-breaking Data From Phase 2 Study In China Testing Varlitinib In Second Line Biliary Tract Cancer At CSCO
ASLAN Pharmaceuticals announced late-breaking topline data from a phase 2 study conducted in China testing varlitinib and capecitabine in second line BTC patients.
9/23/2019Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Abstract on Aslan Pharmactuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019
ASLAN Pharmaceuticals announced that an abstract on its lead candidate, varlitinib, has been accepted for poster presentation at the ESMO Asia Congress 2019 in Singapore on 22 November – 24 November.
New Data From ASLAN’s Study of Varlitinib in China Accepted as Late-breaking Oral Presentation at 2019 CSCO Annual Meeting
ASLAN Pharmaceuticals today announced that a late-breaking abstract detailing results from a phase 2 study of varlitinib in patients with advanced or metastatic biliary tract cancer in China has been accepted for oral presentation at the upcoming 2019 Chinese Society of Clinical Oncology (CSCO) in Xiamen, China on 19 September 2019.
ASLAN Pharmaceuticals names industry veteran and current board member Andrew Howden to additional role of Chairman
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced that Andrew Howden has been elected as non-executive Chairman of the Board.
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the successful completion of its single ascending dose (SAD) study testing the first-in-class therapeutic antibody ASLAN004 in healthy volunteers, and the updated data from the second part of the study that tested a subcutaneous formulation of ASLAN004.
ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has amended its license agreement with CSL Limited (CSL) so that ASLAN has full global rights to develop, manufacture and commercialise ASLAN004 in all indications